Changes after publication

Changes after publication

March 2017: under the original patient access scheme the company provided 2x45‑mg pre-filled syringes, for patients who needed the higher dose of 90‑mg, at the same total cost to the NHS as for a single 45‑mg pre-filled syringe. The patient access scheme has been withdrawn because the company now provides a 90‑mg vial at the same cost as the 45‑mg vial.

February 2014: implementation section updated to clarify that ustekinumab is recommended as an option for treating moderate to severe psoriasis. Additional minor maintenance update also carried out.

ISBN: 978-1-4731-2424-0

  • National Institute for Health and Care Excellence (NICE)